Cardioprotective Effect of Ketamine-dexmeditomidine Versus Fentanyl-midazolam in Open Heart Surgery in Pediatrics

Sponsor
Cairo University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05314569
Collaborator
(none)
81
1
3
5.4
15.1

Study Details

Study Description

Brief Summary

congenital hearts are very sensitive and irritable to deal with, especially during repair defects, the child's heart is exposed to impaired myocardial function during the entire procedure. Moreover, reperfusion of the heart during open-heart surgery when the myocardium is exposed to a global ischaemic cardioplegic arrest can induce myocardial injury. Myocardial reperfusion injury activates neutrophils, which trigger an inflammatory response resulting in the generation of reactive oxygen species (ROS), cytokine release, and complement activation, which further induce more cardiac injury. In addition to the inflammatory response generated as a result of tissue reperfusion injury, there is a significant systemic inflammatory response that is triggered by cardiopulmonary bypass (CPB) during open-heart surgery

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

Myocardial protection is an important issue. This is reflected in the clinical prognosis of patients undergoing cardiac surgery and this can be measured by the most popular Cardiac biomarkers ( cardiac troponin I (cTnI)). (2)

A large number of anesthetic agents have been implicated in protecting the heart against ischemia and reperfusion injury. Ketamine has an anti-inflammatory effect and has been shown to reduce ROS generation by neutrophils and to decrease endotoxin stimulated IL6 production in human whole blood although it does not impair neutrophil function. (3)

Dexmedetomidine is a highly selective, short-acting, central α2-adrenergic agonist with intense sympatholytic qualities. Dexmedetomidine has been increasingly used as a component of general anesthesia, including cardiac surgical applications due to its sedative/hypnotic and analgesic effects which are enhanced by its cardioprotective properties. (4) Riha et.al showed that ketamine - Dexmedetomidine combination had superior cardioprotective effects as measured by cardiac markers as compared to sevoflurane- sufentanil anesthesia after cardiac surgery. (5) Midazolam is known to have potential anti-inflammatory effects and antioxidant activity. They have been proven to provide protective effects for patients who underwent cardiac surgery. (6) Fentanyl is one opioid that has been closely linked to inflammatory mediators and myocardial protection. It reduces the CPB-induced inflammatory response and ischaemic reperfusion injury during cardiac surgery. These effects are related to improvement in intracellular Ca2+ mobilization and do not seem to be related to the adhesion of neutrophils in the coronary system. (7) To the best of our knowledge, this is the first study comparing the combined effect of Ketamine- Dexmedetomidine versus fentanyl- midazolam against ischemia and reperfusion injury in pediatric congenital heart surgery repair.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
81 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
patients will be allocated to three groupspatients will be allocated to three groups
Masking:
Triple (Participant, Care Provider, Investigator)
Masking Description:
patients will be allocated to the study using a computer-generated random list and the group assignments will be sealed in opaque envelopes that will be opened after induction. The drugs will be prepared by an anesthetist who is blind to the study groups.
Primary Purpose:
Supportive Care
Official Title:
Cardioprotective Effect of Ketamine-dexmeditomidine Versus Fentanyl-midazolam in Open-heart Surgery in Pediatrics: A Randomized Controlled Double-blinded Study
Actual Study Start Date :
Apr 15, 2022
Anticipated Primary Completion Date :
Sep 20, 2022
Anticipated Study Completion Date :
Sep 25, 2022

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Control group(C)

anesthesia will be maintained using Isoflurane 1.2MAC keeping the bispectral index( BIS) between 40-60%.

Drug: Isoflurane
Anesthetic inhalational gas

Active Comparator: Ketamine-dexmedetomidine group( KD)

After induction of anesthesia , dexmedetomidine will be given(1 ug /kg ) over 10 min, then ketamine(2 m/kg) . maintenance throughout the procedure, with the bispectral index between 40 and 60%. by infusing Dexmedetomidine( 0.5 μg/.kg /.h r)) ketamine,( 1 m/kg/hr),

Drug: Ketamine- dexmedetomidine
ketamine - Dexmedetomidine combination had superior cardioprotective effects as measured by cardiac markers as compared to sevoflurane- sufentanil anesthesia after cardiac surgery

Active Comparator: . Fentanyl- midazolam group (FM)

After induction of anesthesia fentanyl( 3 μg/kg), midazolam( 100 ug /kg over 2 to 3 minutes) maintenance throughout the procedure, with the bispectral index between 40 and 60%. by infusing midazolam (1 ug /kg /min)-fentanyl( 2 μg/kg/h ).

Drug: Fentanyl- midazolam
Midazolam is known to have potential anti-inflammatory effects and antioxidant activity. They have been proven to provide protective effects for patients who underwent cardiac surgery.Fentanyl is one opioid that has been closely linked to inflammatory mediators and myocardial protection. It reduces the CPB-induced inflammatory response and ischaemic reperfusion injury during cardiac surgery

Outcome Measures

Primary Outcome Measures

  1. troponin level [6 hours]

    mean troponin level post arotic declamping.

Secondary Outcome Measures

  1. heart rates [every 15 minutes]

    records of reading till the end of the surgery

  2. aortic cross clamping [2 hours]

    duration of clamping

  3. inotropic support [6 hours]

    number of patients

  4. blood pressure [every 15 minutes]

    records of reading till the end of the surgery

  5. need of nitroglycerin infusion [6 hours]

    number of patients

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Months to 24 Months
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • the American Society of Anesthesiologists II and III

  • elective open Congenital cardiac surgery(VSD, AV canal, and partial anomaly) using cardiopulmonary bypass

Exclusion Criteria:
  • less than 6 months or more than 24 months.

  • weight < 5 kg.

  • cyanotic heart disease

  • patients with heart failure, an implantable pacemaker, pulmonary hypertension, preoperative administration of inotropic agents, serum creatinine higher than1.5 mg/dL, chronic liver disease, patients receiving sulfonylurea, theophylline, or allopurinol

Contacts and Locations

Locations

Site City State Country Postal Code
1 Amany Hassan Saleh Giza Egypt 02

Sponsors and Collaborators

  • Cairo University

Investigators

  • Principal Investigator: Amany H Saleh, MD, Cairo University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Amany Hassan Saleh, Associate professor of anesthesia ,surgical intensive care and pain management ,Cairo University, Cairo University
ClinicalTrials.gov Identifier:
NCT05314569
Other Study ID Numbers:
  • N-11-2022
First Posted:
Apr 6, 2022
Last Update Posted:
Jul 20, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2022